CSPC Pharmaceutical Group (HKG:1093) said Friday that its Enlida injection for a rare autoimmune disease has been approved for use in China in combination with conventional drugs.

The company said the approval from the National Medical Products Administration followed positive results from a phase III study in China in subjects with generalized myasthenia gravis.